Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MPI | P34949 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26166282 | 0.99 | CYP11B1 (0.32) | CYP11B1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL26166280 | 0.97 | CYP11B1 (0.33) | CYP11B1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL26166277 | 0.97 | CYP11B1 (0.33) | CYP11B1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL26166316 | 0.96 | HSD17B1 (0.33) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL26166190 | 0.95 | CA12 (0.31) | CA12CA1CA2CA9 | |
| SCHEMBL26166281 | 0.95 | HSD17B1 (0.32) | CYP11B1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL26166312 | 0.95 | HSD17B1 (0.33) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL26166286 | 0.95 | GPR84 (0.31) | CYP11B1KDM4EGPR84CA9 | |
| SCHEMBL26166050 | 0.94 | CA12 (0.34) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL26166187 | 0.94 | CA9 (0.31) | KDM4ECA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172066-A1 | LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-01 | — | — | US | disclosed |
| US-20230172066-A1 | LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172066-A1 | LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME | LAGE3, NR2E3, MAOA | CYP11B1 3735/4885KDM4E 454/4885MEN1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.